RE: W2T valuation24 Dec 2019 15:20
There is no right or wrong valuation, no magic figure. At the end of the day the valuation is whatever price the current owners are prepared to sell for, and whatever price the buyers are prepared to pay. The valuation will not be found in the balance sheet of the target company.
Right now both W2T and PHE are in a rut. W2T do not own the DMG technology, they do not hold the IP rights, but they do have the rights (from PHE) to market and develop the DMG units. W2T are trying to promote the first DMG system and raise funds to develop it, but I suspect that financial institutions and investors may be reluctant to provide the required funding because they see that W2T are not in complete control as they do not own the IP.
PHE are also in a bit of a hole. They are not geared up to market the DMG technology on a large scale, and they don't have the funds to develop the first unit. Potential investors may be confused about the roles and responsibilities between W2T and PHE. No doubt this will make them reluctant to invest in PHE.
To add to the confusion, W2T have lately made announcements about the development of "their" DMG technology and have not always acknowledged PHE's involvement.
So it must have become clear to both parties that in order to move forward they must eliminate the confusion between them which can be achieved by combing the two companies, either by take-over or merger. In which case the "valuation" will depend upon what each party believes they will gain by such combination, making the overall business more attractive to potential customers and investors, and thus enabling the business to move forward. The "valuation" will then depend upon negotiation between the two parties.